Search Results for: hepatitis b

April 6, 2017April 6, 2017

ContraVir Reports New Mechanism of Action for Hepatitis B Virus Inhibitor CRV431

Hepatitis B, News

ContraVir Pharmaceuticals, a New Jersey-based biopharma company that develops and commercializes antiviral therapies, is providing new insights into the mechanism of action of its hepatitis B virus (HBV)-optimized cyclophilin inhibitor CRV431. ... Read more

March 30, 2017March 30, 2017

Report Defines Plan to Prevent 90,000 Hepatitis B and C Deaths in US by 2030

Hepatitis B, Hepatitis C, News

With better strategies on prevention, screening, treatment, and creative financing for medications, the U.S. could eradicate hepatitis B and C as public health problems, preventing nearly 90,000 deaths by 2030, according ... Read more

February 14, 2017February 14, 2017

EMA Committee Rules Favorably on VBI Vaccine for Hepatitis B

Hepatitis B, News

A committee of the European Union’s drug regulatory agency has given its blessing to Sci-B-Vac, a vaccine for hepatitis B developed by Massachusetts-based VBI Vaccines. The Committee for Medicinal Products for Human ... Read more

February 9, 2017February 9, 2017

NIH Awards $416,000 to Saint Louis Researchers to Advance Potential Cure for Hepatitis B

Hepatitis B, News

Researchers at Missouri’s Saint Louis University (SLU) — hoping to advance understanding on how hepatitis B virus (HBV) replicates — aim to develop a new drug that could cure this viral infection. John Tavis, PhD, professor of ... Read more

January 24, 2017January 24, 2017

GeoVax and Georgia State Working on Hepatitis B Therapeutic Vaccine

Hepatitis B, News

GeoVax Labs and the Georgia State University Research Foundation have entered a research agreement to develop a therapeutic vaccine for chronic hepatitis B virus (HBV) infections. Georgia State will combine its preS VLP ... Read more

January 17, 2017January 17, 2017

Vemlidy, for Chronic Hepatitis B Infection, Approved in Europe

Hepatitis B, News

The European Union has granted marketing authorization for Vemlidy (tenofovir alafenamide, or TAF), Gilead Sciences’ pioneering treatment for chronic hepatitis B virus (HBV) infection in adults and teens with compensated liver ... Read more

January 5, 2017January 5, 2017

ContraVir Awarded $224K Research Grant to Advance Potential Hepatitis B Treatment

Hepatitis B, News

The National Research Council (NRC) in Canada has awarded ContraVir Pharmaceuticals more than $224,000 to cover expenses related to the preclinical development of CRV431, the company’s cyclophilin inhibitor for the treatment of hepatitis B virus (HBV). The research award, ... Read more

December 22, 2016December 22, 2016

Combo of RNA Interference Therapies and Antiviral Agents Treat Hepatitis B in Early Study

Hepatitis B, News

Treatments combining Benitec Biopharma’s investigative agents — BB-101, BB-102 or BB-103 — with current standard of care may be a way of treating hepatitis B virus (HBV) infection, according to results obtained ... Read more

December 15, 2016December 16, 2016

Health Professionals in Ethiopia Show Solid Knowledge of Hepatitis B in Hospital Survey

Hepatitis B, News

The majority of healthcare professionals working at University of Gondar Hospital in Ethiopia are knowledgeable of hepatitis B transmission and its risks, and the importance of a vaccination program — all important points for people ... Read more

November 15, 2016November 15, 2016

FDA Gives Gilead Sciences’ Vemlidy a Green Light for Hepatitis B Viral Treatment

Hepatitis B, News

Gilead Sciences’ Vemlidy (tenofovir alafenamide) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic hepatitis B virus (HBV) infection with compensated ... Read more